President Trump’s Great Healthcare Plan sets out a framework for reforming the US healthcare system centred on affordability, transparency and accountability. While primarily domestic in intent, the plan signals policy directions with important implications for global private health insurers.

This briefing examines how proposed changes to drug pricing and expanded transparency requirements could affect the financial sustainability of risk-based private insurance markets beyond the United States. It explores potential spillover effects on global pharmaceutical pricing, rising disclosure and reporting expectations for insurers, greater scrutiny of claims management and intermediaries, and increased cost volatility.

The briefing concludes with strategic considerations for private health insurers potentially facing heightened accountability, pricing uncertainty and regulatory risk.